IBDEI0RK ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12409,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12409,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrns Circ Anticoag/Antibodies/Inhibitors
 ;;^UTILITY(U,$J,358.3,12409,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,12409,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,12410,0)
 ;;=D50.9^^49^600^30
 ;;^UTILITY(U,$J,358.3,12410,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12410,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,12410,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,12410,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,12411,0)
 ;;=D64.81^^49^600^3
 ;;^UTILITY(U,$J,358.3,12411,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12411,1,3,0)
 ;;=3^Anemia d/t Antineoplastic Chemotherapy
 ;;^UTILITY(U,$J,358.3,12411,1,4,0)
 ;;=4^D64.81
 ;;^UTILITY(U,$J,358.3,12411,2)
 ;;=^5002349
 ;;^UTILITY(U,$J,358.3,12412,0)
 ;;=D63.1^^49^600^5
 ;;^UTILITY(U,$J,358.3,12412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12412,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,12412,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,12412,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,12413,0)
 ;;=D62.^^49^600^1
 ;;^UTILITY(U,$J,358.3,12413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12413,1,3,0)
 ;;=3^Acute Blood Loss Anemia
 ;;^UTILITY(U,$J,358.3,12413,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,12413,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,12414,0)
 ;;=D51.9^^49^600^36
 ;;^UTILITY(U,$J,358.3,12414,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12414,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,12414,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,12414,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,12415,0)
 ;;=D51.3^^49^600^35
 ;;^UTILITY(U,$J,358.3,12415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12415,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Dietary
 ;;^UTILITY(U,$J,358.3,12415,1,4,0)
 ;;=4^D51.3
 ;;^UTILITY(U,$J,358.3,12415,2)
 ;;=^5002287
 ;;^UTILITY(U,$J,358.3,12416,0)
 ;;=D51.0^^49^600^32
 ;;^UTILITY(U,$J,358.3,12416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12416,1,3,0)
 ;;=3^Pernicious Anemia
 ;;^UTILITY(U,$J,358.3,12416,1,4,0)
 ;;=4^D51.0
 ;;^UTILITY(U,$J,358.3,12416,2)
 ;;=^5002284
 ;;^UTILITY(U,$J,358.3,12417,0)
 ;;=D50.0^^49^600^4
 ;;^UTILITY(U,$J,358.3,12417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12417,1,3,0)
 ;;=3^Anemia d/t Blood Loss (Chronic)
 ;;^UTILITY(U,$J,358.3,12417,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,12417,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,12418,0)
 ;;=E11.21^^49^600^19
 ;;^UTILITY(U,$J,358.3,12418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12418,1,3,0)
 ;;=3^DM Type 2 w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,12418,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,12418,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,12419,0)
 ;;=E11.22^^49^600^9
 ;;^UTILITY(U,$J,358.3,12419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12419,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,12419,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,12419,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,12420,0)
 ;;=E11.29^^49^600^20
 ;;^UTILITY(U,$J,358.3,12420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12420,1,3,0)
 ;;=3^DM Type 2 w/ Other Diabetic Kidney Complication
 ;;^UTILITY(U,$J,358.3,12420,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,12420,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,12421,0)
 ;;=E11.311^^49^600^21
 ;;^UTILITY(U,$J,358.3,12421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12421,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Diabetic Retinopathy w/ Macular edema
